Top 7 drugs most likely to become "blockbusters" in 2022

Recently, Clarivate Analytics analysts released a list of drugs predicted to be "blockbusters" in the future.

Criteria: Based on the "blockbuster" threshold of $1 billion in annual revenue, Clarivate Analytics predicts seven drugs that will reach $16 billion by the end of 2026. Among them, the top two drugs are likely to generate huge benefits.

PART 01

Leading the list is Eli Lilly's diabetes drug tirzepatide, a dual GLP-1/GIP antagonist. Clarivate Analytics forecasts sales of the drug at $4.55 billion in 2026.

PART 02

It is followed by the drug donanemab, also from Eli Lilly and Co., an Alzheimer's drug with projected 2026 sales of around $4.52 billion. The drug is currently undergoing several phase III trials.

PART 03

Another anti-Alzheimer's disease drug from Biogen, Lecanemab, is an anti-Aβ fibrillar monoclonal antibody that is currently applying for breakthrough therapy and awaiting FDA review.

PART 04

Alnylam's RNAi drug Vutrisiran, a drug for the rare disease ATTR (amyloid thyroxine), has few treatment options for a patient population. The drug not only taps into a relatively underserved market overall, but is more convenient than other ATTR-specific drugs on the market, analysts say.

PART 05

Faricimab, the world's first dual VEGF/Ang-2 inhibitor for the treatment of DME (diabetic macular edema) and wet AMD (macular degeneration), is a collaboration between Genentech and Japan's Chugai. Faricimab is similar in efficacy to existing treatments, but is administered less frequently.

PART 06

The anti-KRAS inhibitor adagrasib from Mirati. This is an anti-KRASG12C drug for NSCLC (non-small cell lung cancer) and CRC (colorectal cancer).

The drug received orphan drug and breakthrough therapy designation from the FDA last June. In November 2021, Mirati began its NDA filing.

PART 07

Tezepelumab, a new asthma drug from AstraZeneca. Compared with existing treatments, Tezepelumab can better treat patients with low TH2 and non-TH2 asthma, and the market is broader.